Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

Novel therapies are urgently needed to improve clinical outcomes for patients with acute myeloid leukemia (AML). The investigational drug alisertib (MLN8237) is a novel Aurora A kinase inhibitor being studied in multiple Phase I and II studies. We investigated the preclinical efficacy and pharmacody...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kelly, Kevin R., Nawrocki, Steffan T., Espitia, Claudia M., Zhang, Mengkun, Yang, Johnny J., Padmanabhan, Swaminathan, Ecsedy, Jeffrey, Giles, Francis J., Carew, Jennifer S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3419336/
https://ncbi.nlm.nih.gov/pubmed/22488249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.27579
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky